AINewsnow

MindRank’s oral GLP-1 is the furthest along any AI-native drug programme

This story is from 2026-08-26. It is preserved in the archive; the latest stories are on the live feed.

MindRank, a Hangzhou drug developer built around AI, says its lead candidate went from programme initiation to Phase III trials in roughly four and a half years on about $23mn of cumulative research spending. If that holds up, it is the most concrete answer yet to a question the sector has been ask…

Read the full story at The Next Web ↗

Timeline · 1 report

  1. 2026-08-26 09:36 · The Next Web
    MindRank’s oral GLP-1 is the furthest along any AI-native drug programme

More stories

  1. Introducing Kimi K3 on Amazon Bedrock — AWS Machine Learning Blog
  2. Introducing Amazon SageMaker HyperPod Inference Gateway — AWS Machine Learning Blog
  3. Anthropic, OpenAI, SpaceXAI, Google sued over call to ‘pace’ AI development — Politico Technology
  4. Gemini Hacked Three Companies in First Known Breakout by Google’s AI — Wall Street Journal Technology
  5. Alibaba ships Qwen3.8-Omni-Flash to watch, listen and call tools — r/LocalLLM
  6. NVIDIA CEO Jensen Huang rejects ‘AI will end the world’ claim, yet cautions ‘we should go as fast as we can but...’ — Mint AI
  7. Meet the Data Agent in ChatGPT Work — OpenAI YouTube
  8. AI hallucination of Chinese nuclear components almost led to US military attack — Ars Technica AI

Get the daily brief of stories like this at 6:30 every morning →